Cedric Pobel, MD, discusses how the results of the PEACE-1 trial support the use of radiotherapy plus standard of care and abiraterone in low-volume metastatic castration-sensitive prostate cancer.

Adding pembrolizumab to docetaxel did not significantly improve outcomes in previously treated patients with mCRPC.